Olema Pharmaceuticals, Inc. Overview
Pro stress-test →Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of therapies for women's cancers. The company is advancing palazestrant, an estrogen receptor antagonist and selective ER degrader, through Phase 3 clinical trials for ER+/HER2- metastatic breast cancer. Strategic partnerships and multiple trial phases position Olema for potential FDA approval and market entry by 2027.
Strategic Profile
Pro stress-test →Olema leverages advanced scientific methods to develop treatments addressing challenges of both wild-type and mutant estrogen receptor-positive diseases. Beyond palazestrant, the company is developing OP-3136, a KAT6 inhibitor being evaluated in combination with endocrine therapies to enhance anti-tumor efficacy. The company's precision medicine approach targets treatment resistance mechanisms in hormone-driven cancers.
Competitive Landscape
Pro stress-test →Olema competes in the targeted oncology space against established players developing next-generation endocrine therapies for ER+ breast cancer. Competitors include large pharma companies with approved ER-targeted agents and other biotech firms in clinical development. Recent Roche Phase 3 results for giredestrant in early-stage breast cancer elevated competitive intensity, though Olema's dual-mechanism ER antagonist/degrader approach offers differentiation.
Industry Context
Olema Pharmaceuticals, Inc. operates in Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics).
Key facts
Founded: 2006 · Headquarters: San Francisco, California · Employees: 116 · Revenue: $0 · Market cap: $0.6B